Pfizer Price to Free Cash Flow Ratio 2012-2025 | PFE
Historical price to free cash flow ratio values for Pfizer (PFE) since 2012.
| Pfizer Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-01-14 | 25.58 | 14.06 | |
| 2025-09-30 | 25.04 | $1.82 | 13.77 |
| 2025-06-30 | 23.42 | $2.18 | 10.73 |
| 2025-03-31 | 24.02 | $1.97 | 12.21 |
| 2024-12-31 | 24.74 | $1.73 | 14.34 |
| 2024-09-30 | 26.57 | $1.44 | 18.45 |
| 2024-06-30 | 25.34 | $0.84 | 30.10 |
| 2024-03-31 | 24.75 | $0.89 | 27.67 |
| 2023-12-31 | 25.30 | $0.84 | 30.13 |
| 2023-09-30 | 28.76 | $1.42 | 20.26 |
| 2023-06-30 | 31.46 | $1.85 | 17.00 |
| 2023-03-31 | 34.61 | $3.53 | 9.81 |
| 2022-12-31 | 43.08 | $4.54 | 9.49 |
| 2022-09-30 | 36.47 | $4.10 | 8.90 |
| 2022-06-30 | 43.37 | $4.97 | 8.73 |
| 2022-03-31 | 42.47 | $5.55 | 7.65 |
| 2021-12-31 | 48.08 | $5.23 | 9.19 |
| 2021-09-30 | 34.71 | $5.21 | 6.66 |
| 2021-06-30 | 31.32 | $3.73 | 8.40 |
| 2021-03-31 | 28.70 | $2.39 | 12.02 |
| 2020-12-31 | 28.84 | $2.16 | 13.34 |
| 2020-09-30 | 27.01 | $1.87 | 14.44 |
| 2020-06-30 | 23.83 | $2.29 | 10.39 |
| 2020-03-31 | 23.55 | $2.12 | 11.11 |
| 2019-12-31 | 27.98 | $1.86 | 15.06 |
| 2019-09-30 | 25.42 | $1.99 | 12.80 |
| 2019-06-30 | 30.36 | $2.07 | 14.69 |
| 2019-03-31 | 29.50 | $2.27 | 13.01 |
| 2018-12-31 | 30.06 | $2.32 | 12.98 |
| 2018-09-30 | 30.12 | $2.68 | 11.25 |
| 2018-06-30 | 24.58 | $2.63 | 9.35 |
| 2018-03-31 | 23.82 | $2.51 | 9.48 |
| 2017-12-31 | 24.08 | $2.45 | 9.83 |
| 2017-09-30 | 23.52 | $2.27 | 10.38 |
| 2017-06-30 | 21.92 | $2.23 | 9.82 |
| 2017-03-31 | 22.11 | $2.29 | 9.65 |
| 2016-12-31 | 20.78 | $2.33 | 8.91 |
| 2016-09-30 | 21.45 | $2.15 | 9.99 |
| 2016-06-30 | 22.12 | $2.21 | 10.03 |
| 2016-03-31 | 18.45 | $2.30 | 8.04 |
| 2015-12-31 | 19.90 | $2.12 | 9.37 |
| 2015-09-30 | 19.21 | $2.25 | 8.52 |
| 2015-06-30 | 20.34 | $2.16 | 9.44 |
| 2015-03-31 | 20.94 | $2.13 | 9.81 |
| 2014-12-31 | 18.58 | $2.47 | 7.51 |
| 2014-09-30 | 17.49 | $2.37 | 7.37 |
| 2014-06-30 | 17.40 | $2.61 | 6.66 |
| 2014-03-31 | 18.66 | $2.51 | 7.44 |
| 2013-12-31 | 17.65 | $2.39 | 7.39 |
| 2013-09-30 | 16.43 | $2.27 | 7.23 |
| 2013-06-30 | 15.89 | $2.00 | 7.93 |
| 2013-03-31 | 16.23 | $2.01 | 8.07 |
| 2012-12-31 | 13.99 | $2.05 | 6.81 |
| 2012-09-30 | 13.73 | $2.04 | 6.73 |
| 2012-06-30 | 12.59 | $1.94 | 6.50 |
| 2012-03-31 | 12.28 | $2.15 | 5.72 |
| 2011-12-31 | 11.61 | $2.36 | 4.92 |
| 2011-09-30 | 9.39 | $2.49 | 3.78 |
| 2011-06-30 | 10.82 | $2.75 | 3.93 |
| 2011-03-31 | 10.57 | $2.60 | 4.06 |
| 2010-12-31 | 9.02 | $1.23 | 7.32 |
| 2010-09-30 | 8.75 | $1.08 | 8.07 |
| 2010-06-30 | 7.19 | $0.86 | 8.38 |
| 2010-03-31 | 8.56 | $0.93 | 9.18 |
| 2009-12-31 | 8.99 | $2.18 | 4.12 |
| 2009-09-30 | 8.10 | $2.45 | 3.31 |
| 2009-06-30 | 7.27 | $2.40 | 3.02 |
| 2009-03-31 | 6.53 | $2.47 | 2.65 |
| 2008-12-31 | 8.31 | $2.45 | 3.39 |
| 2008-09-30 | 8.50 | $2.07 | 4.12 |
| 2008-06-30 | 7.92 | $2.16 | 3.66 |
| 2008-03-31 | 9.34 | $1.94 | 4.82 |
| 2007-12-31 | 10.00 | $1.65 | 6.05 |
| 2007-09-30 | 10.62 | $1.74 | 6.11 |
| 2007-06-30 | 10.99 | $1.61 | 6.84 |
| 2007-03-31 | 10.74 | $1.78 | 6.02 |
| 2006-12-31 | 10.89 | $2.14 | 5.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $142.996B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1018.358B | 48.99 |
| Johnson & Johnson (JNJ) | United States | $514.746B | 20.58 |
| AbbVie (ABBV) | United States | $390.150B | 23.36 |
| Roche Holding AG (RHHBY) | Switzerland | $339.804B | 0.00 |
| Novartis AG (NVS) | Switzerland | $299.140B | 15.86 |
| Merck (MRK) | United States | $268.704B | 12.52 |
| Novo Nordisk (NVO) | Denmark | $266.293B | 15.61 |
| Sanofi (SNY) | France | $115.121B | 11.13 |
| Bayer (BAYRY) | Germany | $44.563B | 7.82 |
| Innoviva (INVA) | United States | $1.459B | 7.31 |